Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway
dc.contributor.author | Monaghan, Tanya | |
dc.contributor.author | Mullish, Benjamin H. | |
dc.contributor.author | Patterson, Jordan | |
dc.contributor.author | Wong, Gane KS | |
dc.contributor.author | Marchesi, Julian R. | |
dc.contributor.author | Xu, Huiping | |
dc.contributor.author | Jilani, Tahseen | |
dc.contributor.author | Kao, Dina | |
dc.date.accessioned | 2019-01-25T19:50:35Z | |
dc.date.available | 2019-01-25T19:50:35Z | |
dc.date.issued | 2018-09-05 | |
dc.description.abstract | The mechanisms of efficacy for fecal microbiota transplantation (FMT) in treating recurrent Clostridioides difficile infection (rCDI) remain poorly defined, with restored gut microbiota-bile acid interactions representing one possible explanation. Furthermore, the potential implications for host physiology of these FMT-related changes in gut bile acid metabolism are also not well explored. In this study, we investigated the impact of FMT for rCDI upon signalling through the farnesoid X receptor (FXR)-fibroblast growth factor (FGF) pathway. Herein, we identify that in addition to restoration of gut microbiota and bile acid profiles, FMT for rCDI is accompanied by a significant, sustained increase in circulating levels of FGF19 and reduction in FGF21. These FGF changes were associated with weight gain post-FMT, to a level not exceeding the pre-rCDI baseline. Collectively, these data support the hypothesis that the restoration of gut microbial communities by FMT for rCDI is associated with an upregulated FXR-FGF pathway, and highlight the potential systemic effect of FMT. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Monaghan, T., Mullish, B. H., Patterson, J., Wong, G. K., Marchesi, J. R., Xu, H., … Kao, D. (2018). Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. Gut Microbes, 0(0), 1–7. https://doi.org/10.1080/19490976.2018.1506667 | en_US |
dc.identifier.issn | 1949-0976 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/18256 | |
dc.language.iso | en_US | en_US |
dc.publisher | Taylor & Francis | en_US |
dc.relation.isversionof | 10.1080/19490976.2018.1506667 | en_US |
dc.relation.journal | Gut Microbes | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
dc.source | Publisher | en_US |
dc.subject | Microbiota | en_US |
dc.subject | fecal microbiota transplantation (FMT) | en_US |
dc.subject | recurrent Clostridium difficile infection (rCDI) | en_US |
dc.subject | bile acid metabolism | en_US |
dc.subject | fibroblast growth factor (FGF)19 | en_US |
dc.title | Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway | en_US |
dc.type | Article | en_US |